However, research on this pentadecapeptide is primarily animal-based and in vitro , with no published full-text clinical studies despite some authors mentioning a phase 1 trial on BPC-157 as an anti-ulcerative agent in IBD patients [6]
In the databases of adverse drug events in multiple countries, the number of reports of mood changes, suicidal ideation and depression related to GLP-1RA has been on the rise, prompting regulatory authorities to request further monitoring [13, 15, 26, 27]
BPC-157 BPC-157, or Body Protection Compound 157, is commonly discussed in tissue-support, structural-integrity, barrier-function, and repair-category research models
A systematic review of the musculoskeletal literature published on NIH/PMC concluded that BPC-157 shows promise for promoting recovery from musculoskeletal injuries across level IV and level V study evidence, covering preclinical data on fractures, tendon ruptures, ligament tears and muscle injuries
Other GLP-1 drugs can do the trick